Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Regeneron Pharmaceuticals (NASDAQ:REGN) Full Year 2024 Results

Key Financial Results

• Revenue: US$14.2b (up 8.3% from FY 2023).
• Net income: US$4.41b (up 12% from FY 2023).
• Profit margin: 31% (up from 30% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: US$40.90 (up from US$37.05 in FY 2023).

REGN Products In Clinical Trials

• Phase II: 28.
• Phase III: 20.

REGN Post-Clinical Trial Products

• Pre-registration: 8.
• Approved (during full year): 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Regeneron Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%.

In the last 12 months, the only revenue segment was Biotechnology contributing US$14.2b. Notably, cost of sales worth US$7.10b amounted to 50% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$2.95b (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$267.5m. Explore how REGN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 6.5% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Regeneron Pharmaceuticals' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.